Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06132165 · ClinicalTrials.gov registry record · Phase 1
Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
A Phase 1 study of Neurofibromatosis 1, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT06132165 is a Phase 1 study of Neurofibromatosis 1 that has completed, run by Massachusetts General Hospital. The registered enrollment target is 13 participants, below the 1,035-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06132165, a Phase 1 study of Neurofibromatosis 1, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effectiveness of skin cooling in increasing tolerability of four treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 980nm laser, a 755nm laser, radio-frequency injection, and a Kybella injection. Each patient will have a treatment and a control site..
Conditions Studied
Interventions
- DEVICE 755nm Alexandrite Laser
- DRUG Deoxycholic Acid
- DRUG Polidocanol
- DEVICE 1064nm Nd:YAG laser
Study Locations (1)
Massachusetts
- Wellman Center for Photomedicine - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2025-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06132165
The ClinicalTrials.gov registry entry for NCT06132165 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,035-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (99% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neurofibromatosis 1 appearing as the primary indexed condition, and to 4 interventions - of which 755nm Alexandrite Laser is the first listed.
NCT06132165 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06132165 about?
NCT06132165 is a clinical study titled "Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas". This study will evaluate the effectiveness of skin cooling in increasing tolerability of four treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 980nm laser, a 755nm laser, radio-frequency injection, and a Kybella injection. Each patient will have a treatment and...
What is the current status of trial NCT06132165?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2024-03-01. Estimated completion is 2025-07-31.
What conditions does trial NCT06132165 study?
This clinical trial studies the following conditions: Neurofibromatosis 1.
What interventions are being tested in trial NCT06132165?
The interventions under investigation include: 755nm Alexandrite Laser (DEVICE), Deoxycholic Acid (DRUG), Polidocanol (DRUG), 1064nm Nd:YAG laser (DEVICE).
Who is sponsoring clinical trial NCT06132165?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06132165 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatosis 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
RECRUITING · Phase 1
-
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
RECRUITING · Phase 1
-
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
ACTIVE NOT RECRUITING · Phase 1
-
NF-1, Nutraceutical Intervention
ACTIVE NOT RECRUITING · Phase 1
-
Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.